Johnson & Johnson (JNJ)
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
📈 **POSITIVE** • Low confidence analysis (52%) • Moderate positive clinical data • Good growth prospects **Sentiment:** Positive (55%) **Content type:** Clinical